Rank | Product | Manufacturer | 2016 U.S. Sales $ (millions) | 2015 U.S. Sales $ (millions) | Vs. 2015 | 1Q 2017 U.S. Sales $ (millions) | 1Q 2016 U.S. Sales $ (millions) | Vs. 2016 |
---|---|---|---|---|---|---|---|---|
1 | Prevnar / Prevnar 13 | Pfizer | $3,645 | $4,026 | -9% | $938 | $1,031 | -9% |
2 | Gardasil / Gardasil 9 | Merck | $1,780 | $1,520 | 17% | $398 | $320 | 24% |
3 | Fluzone* | Sanofi | $1,236 | $994 | 24% | – | – | N/A |
4 | Varivax | Merck | $792 | $686 | 15% | $159 | $158 | 1% |
5 | Menactra | Sanofi | $571 | $548 | 4% | – | $113 | N/A |
6 | Zostavax | Merck | $518 | $592 | -13% | $109 | $109 | 0% |
7 | Proquad | Merck | $495 | $454 | 9% | $103 | $122 | -16% |
8 | RotaTeq | Merck | $482 | $447 | 8% | $178 | $149 | 19% |
9 | Pediarix | GlaxoSmithKline | $458 | $411 | 11% | $155 | $112 | 38% |
10 | Pentacel | Sanofi | $448 | $436 | 3% | $135 | $66 | 105% |
11 | Pneumovax | Merck | $447 | $378 | 18% | $114 | $67 | 70% |
12 | FluLaval / Fluarix | GlaxoSmithKline | $427 | $301 | 42% | – | – | N/A |
13 | Hepatitis Vaccine Franchise | GlaxoSmithKline | $398 | $417 | -5% | $105 | $89 | 18% |
14 | M-M-R II | Merck | $353 | $365 | -3% | $92 | $76 | 21% |
15 | Adacel* | Sanofi | $334 | $399 | -16% | $48 | $56 | -14% |
16 | Boostrix | GlaxoSmithKline | $322 | $319 | 1% | $67 | $52 | 29% |
17 | Recombivax HB* | Merck | $188 | $187 | 0% | – | – | N/A |
18 | Rotarix | GlaxoSmithKline | $175 | $212 | -18% | $67 | $60 | 12% |
19 | Bexsero | GlaxoSmithKline | $165 | $26 | 536% | $33 | $23 | 43% |
20 | Menveo | GlaxoSmithKline | $164 | $151 | 8% | $24 | $31 | -23% |
21 | Avaxim | Sanofi | $139 | $123 | 13% | $31 | $26 | 19% |
22 | Trumenba | Pfizer | $88 | $45 | 94% | – | – | N/A |
23 | Menomune | Sanofi | $52 | $57 | -8% | – | $12 | N/A |
24 | FluMist | AstraZeneca | $33 | $206 | -84% | – | $5 | N/A |
25 | Ixiaro | Valneva | $32 | – | N/A | – | – | N/A |
* indicates sales figures for this product represent franchise-level sales that have been assigned by Evaluate to the lead product in the franchise
Source: EvaluatePharma, August 2017, Evaluate, www.evaluate.com
From the September 01, 2017 Issue of MM+M - Medical Marketing and Media